Clinical implications of postoperative carbohydrate antigen 19-9 as a serological indicator of positive resection margin and occult distant metastasis in patients with resected pancreatic cancer

Clinical implications of postoperative carbohydrate antigen 19-9 as a serological indicator of positive resection margin and occult distant metastasis in patients with resected pancreatic cancer - Clinical implications of postoperative carbohydrate antigen 19-9 in patients with resected pancreatic cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034453

Enrollment

166

Registered

2018-10-11

Start date

2018-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic ductal adenocarcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with surgical resection for pancreatic ductal adenocarcinoma between January 2008 and December 2016 were included in the analysis.

Exclusion criteria

Exclusion criteria: Patients with macroscopically positive resection margin or distant metastasis were excluded. Patients with Pre-CA 19-9 < 5 U/ml were excluded. CA 19-9 values were not included in the analysis if serum total bilirubin was >2.0 mg/dl at the time of assay.

Design outcomes

Primary

Measure	Time frame
Independent prognostic factors were identified using univariate and multivariate Cox-proportional hazard models including pathological and postoperative clinical variables.	—

Secondary

Measure	Time frame
Univariate and multivariate logistic regression analysis were used to identify factors that were independent predictive factors of elevated Post-CA 19-9.	—

Countries

Japan

Contacts

Public ContactTakagi Chisato

Tochigi Cancer Center Hepato-Biliary-Pancreatic Surgery

chtakagi@tochigi-cc.jp028-658-5151

Outcome results